Pricing Log in Create free account
Saturday 17 October 2026 Export OPRX’s income statement to Excel — free account

OptimizeRx Corp.

OPRX Healthcare Health Information Services

OptimizeRx Corp.’s revenue for fiscal 2025 (year ended December 2025) was $109.4 million, up 18.8% from fiscal 2024. In the quarter to June 2026, revenue fell 29.8%, EPS fell 150.0%, free cash flow grew 89.9% and total debt fell 33.1%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.

8.50 0.35 −3.95%
Market cap
$166.7M
P/E
35.4×
Fwd P/E
23.0×
Dividend yield
—
F-score
8/9
Altman Z
3.31
Beneish M
−2.77
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.02
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — 1 — — — — — — — — — —
Insider Ownership 14.78%

Capital & Financial Ratios $m

Market Cap 166.70
Revenue 98.65
Net Income 4.60
Free Cash Flow 18.57
Net Debt (5.09)
Current Ratio 5.58 (at or above 1.5: strong)
Debt/Equity 0.15 (at or below 0.5: strong)
P/E ratio 35.42 (above 35: high)
Fwd P/E 23.00
P/S ratio 1.62
P/B ratio 1.22
Past 5Y EPS Growth —
This Y EPS Growth (14.60%) (below 0%: weak)
Next Y EPS Growth 20.63% (at or above 15%: strong)
Next Y revenue growth (12.06%) (below 0%: weak)
Next 5Y EPS Growth 0.63%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.6×, against a ten-year median of 3.4×; over the ten years it ranged from 0.9× in 2026 to 28.2× in 2021.
P/S against its own 10 years 10.69%
10-year low 10-year high
P/B against its own 10 years 12.42%
10-year low 10-year high
EV/Sales against its own 10 years 12.35%
10-year low 10-year high
EV/FCF against its own 10 years 10.92%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 14 13 23 24
Receivables 37 38 39 27
Inventory — — — —
Other — — — —
54 54 65 54
2023 2024 2025 Q'26
Payables 2 2 2 1
ST’ Debt 2 2 4 1
Other — — — —
18 19 21 10

Compound Annual Growth %

10y 5y 3y
Sales 31.24% 20.37% 20.56%
Cash Flow 43.23% 0.00% 20.66%
Earnings 0.00% 0.00% 0.00%
Book Value 30.52% 20.75% 0.57%

Revenue $m

Mar Jun Sep Dec Year
’26 20 21 — — —
’25 22 29 26 32 109
’24 20 19 21 32 92
’23 13 14 16 28 72
’22 14 14 15 20 62
’21 11 14 16 20 61
’20 8 9 11 16 43
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 0 9 — — —
’25 4 5 3 7 19
’24 2 1 2 0 5
’23 0 (2) 1 (6) (7)
’22 4 0 3 3 11
’21 2 0 0 (1) 1
’20 (4) 0 0 (3) (6)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 0 9 — — —
’25 4 5 3 7 19
’24 2 1 2 0 4
’23 0 (3) 1 (5) (8)
’22 4 0 3 3 10
’21 2 0 0 (1) 0
’20 (4) 0 0 (3) (6)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.03) (0.04) — — —
’25 (0.12) 0.08 0.04 0.26 0.27
’24 (0.38) (0.22) (0.50) 0.00 (1.10)
’23 (0.37) (0.24) (0.17) (0.23) (1.91)
’22 (0.21) (0.21) (0.19) (0.02) (0.64)
’21 (0.04) 0.02 0.00 0.03 0.02
’20 (0.15) (0.07) (0.02) 0.08 (0.15)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 1.95 1.89 3.36 8.63 6.50 31.90 13.33 6.92 3.78 3.99

Analyst estimates 2026–2028

Powerpack
High 3.72 4.80 18.39 17.24 34.22 99.18 64.22 19.98 16.65 22.25
People
People Employees 20 24 37 50 57 82 110 117 107 105
Revenue/emp, $m 0.39 0.51 0.57 0.49 0.76 0.75 0.57 0.61 0.86 1.04
Income, $m
Income, $m Revenue 8 12 21 25 43 61 62 72 92 109
Gross margin, % 55.99 49.09 57.56 62.77 55.65 58.14 62.40 59.98 64.45 67.25
EBT (2) (2) 0 (4) (2) 0 (11) (25) (19) 7
EBT margin, % (19.86) (17.35) 1.07 (16.43) (5.10) 0.62 (18.32) (35.18) (21.04) 6.35
Net income (2) (2) 0 (3) (2) 0 (11) (18) (20) 5
Depreciation 0 0 0 1 2 2 2 3 5 5
Per share, $
Per share, $ Revenue 0.78 1.24 1.96 1.84 2.92 3.56 3.51 4.18 5.04 5.90
Earnings (0.15) (0.21) 0.02 (0.23) (0.15) 0.02 (0.64) (1.91) (1.10) 0.28
Cash flow (0.05) (0.15) 0.07 (0.12) (0.43) 0.04 0.60 (0.42) 0.27 1.01
Capex (0.04) 0.00 (0.01) (0.12) (0.01) (0.03) (0.01) (0.05) (0.02) 0.00
Free cash flow (0.08) (0.15) 0.06 (0.24) (0.43) 0.01 0.59 (0.47) 0.24 1.01
Book value 0.79 0.63 1.70 3.35 3.37 7.63 7.09 7.39 6.40 6.91
Shares, m 10 10 11 13 15 17 18 17 18 19
Valuation, ×
Valuation, × P/E 0.00 0.00 529.95 0.00 0.00 2,736.12 0.00 0.00 0.00 45.41
P/S 3.10 3.74 5.60 5.59 10.67 17.46 4.88 3.36 0.97 2.08
P/B 3.08 7.29 6.44 3.06 9.25 8.14 2.41 1.90 0.76 1.77
EV/Sales 2.20 3.32 5.18 4.85 10.44 16.08 3.69 3.67 1.18 2.10
EV/FCF (20.88) (23.34) 156.69 (36.70) (56.96) 4,106.99 22.15 (33.01) 24.43 12.24
Cash, $m
Cash, $m Operating cash flow 0 (1) 1 (2) (6) 1 11 (7) 5 19
Capex 0 0 0 (2) 0 0 0 (1) 0 0
Free cash flow (1) (2) 1 (3) (6) 0 10 (8) 4 19
Balance, $m
Balance, $m Working capital 7 5 12 21 23 106 90 36 35 43
Total debt — — — 1 0 0 0 36 33 26
Net debt (7) (5) (9) (18) (10) (84) (74) 22 19 2
Shareholders’ equity 8 6 18 45 50 131 126 127 117 128
Returns, %
Returns, % ROA (12.94) (19.81) 1.30 (7.69) (3.77) 0.38 (8.30) (11.05) (11.34) 2.95
ROIC (127.11) (121.25) 1.18 (8.69) (3.34) 0.48 (14.71) (11.08) (6.28) 5.60
ROE (18.37) (29.99) 1.83 (9.93) (4.65) 0.42 (8.88) (13.90) (16.51) 4.18
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

OptimizeRx Corp. vs peers in Health Information Services (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
CSLT Castlight Health, inc. $332.4M — (loss-making) — (loss-making) −0.86% (below 0%: shrinking) n/m +106.49% (above 0%: growing) 66.20% (5.42%) Compare
SPOK Spok Holdings, Inc. $224.5M 17.7× 16.2× −1.89% (below 0%: shrinking) −9.09% (below 0%: shrinking) −2.00% (below 0%: shrinking) 80.47% 15.50% Compare
AMWL American Well Corporation $210.6M — (loss-making) — (loss-making) −26.59% (below 0%: shrinking) n/m +266.38% (above 0%: growing) 52.95% (18.36%) Compare
SY So-Young International Inc. Sponsored ADR $198.9M — (loss-making) 12.8× +40.84% (above 0%: growing) n/m −798.37% (below 0%: shrinking) 44.11% (8.64%) Compare
OPRX OptimizeRx Corp. $166.7M 35.4× 23.0× −29.77% (below 0%: shrinking) n/m +89.86% (above 0%: growing) 76.51% (0.43%)
DH Definitive Healthcare Corp. $144.3M — (loss-making) — (loss-making) −9.14% (below 0%: shrinking) n/m +21.44% (above 0%: growing) 73.45% (12.23%) Compare
HCAT Health Catalyst, Inc. $135.5M — (loss-making) — (loss-making) −12.68% (below 0%: shrinking) n/m +64.26% (above 0%: growing) 49.46% (51.75%) Compare
LFMD LifeMD, Inc. $118.6M — (loss-making) — (loss-making) −3.55% (below 0%: shrinking) n/m −247.52% (below 0%: shrinking) 88.82% (15.08%) Compare
CCLD CareCloud, Inc. $82.0M 26.4× 12.5× +16.45% (above 0%: growing) n/m +6.15% (above 0%: growing) 45.24% 5.84% Compare
Median of peers $171.6M — 12.8× −2.72% — +13.80% 59.58% (10.43%)

All 51 Health Information Services stocks →

OptimizeRx Corp. (OPRX) key facts

  • Strength: OptimizeRx Corp.’s revenue for fiscal 2025 (year ended December 2025) was $109.4 million, up 18.8% from fiscal 2024.
  • OptimizeRx Corp. (OPRX) is a Health Information Services company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, OPRX traded at $8.50, a market capitalization of $166.7 million.
  • Return on equity was 4.18% and debt-to-equity 0.14.
  • Its Piotroski F-score is 8 out of 9 and its Altman Z-score is 3.31 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

OptimizeRx Corp. (OPRX) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/OPRX · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com